Premium
Combination of caspofungin and low‐dose trimethoprim/sulfamethoxazole for the treatment of severe P neumocystis jirovecii pneumonia in renal transplant recipients
Author(s) -
Tu Guowei,
Ju Minjie,
Xu Ming,
Rong Ruiming,
He Yizhou,
Xue Zhanggang,
Zhu Tongyu,
Luo Zhe
Publication year - 2013
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/nep.12133
Subject(s) - medicine , caspofungin , trimethoprim , pneumonia , sulfamethoxazole , incidence (geometry) , adverse effect , renal transplant , complication , transplantation , antibiotics , surgery , dermatology , microbiology and biotechnology , antifungal , physics , optics , biology , amphotericin b
P neumocystis jirovecii pneumonia ( PJP ) is a severe and life‐threatening complication in immunocompromised patients. Trimethoprim/sulfamethoxazole ( TMP‐SMZ ) is well known for its effectiveness as prophylaxis of PJP . However, the use of TMP‐SMZ is associated with various adverse effects that may not be tolerated by critically ill patients. Caspofungin is recommended for invasive fungal infections, but the treatment of PJP after solid organ transplantation ( SOT ) is an off‐label use of this drug. In this study, three cases of severe PJP in renal transplant recipients treated with a combination of caspofungin and low‐dose TMP‐SMZ were presented. Initial findings indicated that the combined treatment may be beneficial for the treatment of PJP and decrease the incidence of TMP‐SMZ ‐related adverse effects.